Lecozotan (developmental code name SRA-333) is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients. , the first Phase III clinical trial has been completed.ClinicalTrials
Method of action Lecozotan is a competitive, selective 5-HT1A receptor antagonist which enhances the potassium-stimulated release of acetylcholine and glutamate.
References